title: Nonopsonic monocyte/macrophage phagocytosis of Plasmodium falciparum-parasitized erythrocytes: a role for CD36 in malarial clearance.
abstract: Plasmodium falciparum is the most lethal form of malaria and is increasing both in incidence and in its resistance to antimalarial agents. An improved understanding of the mechanisms of malarial clearance may facilitate the development of new therapeutic interventions. We postulated that the scavenger receptor CD36, an important factor in cytoadherence of P falciparum-parasitized erythrocytes (PEs), might also play a role in monocyte- and macrophage-mediated malarial clearance. Exposure of nonopsonized PEs to Fc receptor-blocked monocytes resulted in significant PE phagocytosis, accompanied by intense clustering of CD36 around the PEs. Phagocytosis was blocked 60% to 70% by monocyte pretreatment with monoclonal anti-CD36 antibodies but not by antibodies to alpha(v)beta(3), thrombospondin, intercellular adhesion molecule-1, or platelet/endothelial cell adhesion molecule-1. Antibody-induced CD36 cross-linking did result in the early increase of surface CD11b expression, but there was no increase in, or priming for, tumor necrosis factor (TNF)-alpha secretion following either CD36 cross-linking or PE phagocytosis. CD36 clustering does support intracellular signaling: Antibody-induced cross-linking initiated intracellular tyrosine phosphorylation as well as extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) phosphorylation. Both broad-spectrum tyrosine kinase inhibition (genistein) and selective ERK and p38 MAPK inhibition (PD98059 and SB203580, respectively) reduced PE uptake to almost the same extent as CD36 blockade. Thus, CD36-dependent binding and signaling appears to be crucial for the nonopsonic clearance of PEs and does not appear to contribute to the increase in TNF-alpha that is prognostic of poor outcome in clinical malaria.
authors.affiliation: Departments of Medicine and Surgery, University of Toronto, Toronto, Ontario, Canada.
authors.forename: I D
authors.initials: ID
authors.lastname: McGilvray
authors.forename: L
authors.initials: L
authors.lastname: Serghides
authors.forename: A
authors.initials: A
authors.lastname: Kapus
authors.forename: O D
authors.initials: OD
authors.lastname: Rotstein
authors.forename: K C
authors.initials: KC
authors.lastname: Kain
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000097:blood; D018955:CD36 Antigens / Q000502:physiology*; D002448:Cell Adhesion; D002478:Cells, Cultured; D004912:Erythrocytes / Q000469:parasitology*; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D016177:Macrophage-1 Antigen / Q000032:analysis; D008264:Macrophages / Q000187:drug effects / Q000502:physiology*; D016778:Malaria, Falciparum / Q000097:blood; D020928:Mitogen-Activated Protein Kinases / Q000097:blood; D009000:Monocytes / Q000187:drug effects / Q000502:physiology*; D010587:Phagocytosis; D010766:Phosphorylation; D010963:Plasmodium falciparum / Q000472:pathogenicity*; D012016:Reference Values; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis; D048051:p38 Mitogen-Activated Protein Kinases
chemical_list: D015703:Antigens, CD; D018955:CD36 Antigens; D008070:Lipopolysaccharides; D016177:Macrophage-1 Antigen; D014409:Tumor Necrosis Factor-alpha; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases